Production (Stage)
Atai Life Sciences N.V.
ATAI
$2.32
$0.010.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -340.76% | -271.09% | -92.11% | 59.97% | 77.26% |
| Total Depreciation and Amortization | 79.82% | 48.28% | 28.78% | 45.92% | 94.80% |
| Total Amortization of Deferred Charges | 46.25% | 38.81% | 5.71% | 29.61% | 81.69% |
| Total Other Non-Cash Items | 248.21% | 244.17% | 284.89% | -154.33% | -214.26% |
| Change in Net Operating Assets | -390.87% | -223.18% | -421.22% | 75.83% | -167.77% |
| Cash from Operations | 9.20% | 2.00% | 13.55% | 22.57% | 15.76% |
| Capital Expenditure | -4,976.19% | 97.68% | 97.96% | 99.06% | 102.11% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 200.00% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 165.05% | 211.84% | 81.91% | -113.54% | -139.63% |
| Cash from Investing | 163.43% | 211.03% | 87.78% | -113.94% | -140.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 319,394.74% | 137.78% | 21.21% | -94.06% | -99.73% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 91.55% | 98.12% | -654.01% | -359.62% | -649.34% |
| Cash from Financing | 859.01% | 164.32% | -297.18% | -142.89% | -141.04% |
| Foreign Exchange rate Adjustments | 1,447.06% | 91.53% | 118.00% | -29.41% | 97.31% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 116.06% | 87.96% | 52.26% | -287.43% | -345.55% |